Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3).

Autor:	Girardi F; Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.; Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK.; Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy., Matz M; Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK., Stiller C; National Cancer Registration and Analysis Service, Public Health England, London, UK., You H; Cancer Information Analysis Unit, Cancer Institute NSW, St Leonards, New South Wales, Australia., Marcos Gragera R; Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Girona, Spain., Valkov MY; Department of Radiology, Radiotherapy and Oncology, Northern State Medical University, Arkhangelsk, Russia., Bulliard JL; Centre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.; Neuchâtel and Jura Tumour Registry, Neuchâtel, Switzerland., De P; Surveillance and Cancer Registry, and Research Office, Clinical Institutes and Quality Programs, Ontario Health, Toronto, Ontario, Canada., Morrison D; Scottish Cancer Registry, Public Health Scotland, Edinburgh, UK., Wanner M; Cancer Registry Zürich, Zug, Schaffhausen and Schwyz, University Hospital Zürich, Zürich, Switzerland., O'Brian DK; Alaska Cancer Registry, Alaska Department of Health and Social Services, Anchorage, Alaska, USA., Saint-Jacques N; Department of Medicine and Community Health and Epidemiology, Centre for Clinical Research, Dalhousie University, Halifax, Nova Scotia, Canada., Coleman MP; Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.; Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK., Allemani C; Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.
Jazyk:	angličtina
Zdroj:	Neuro-oncology [Neuro Oncol] 2023 Mar 14; Vol. 25 (3), pp. 580-592.
DOI:	10.1093/neuonc/noac217
Abstrakt:	Background: Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in survival from brain tumors in adults, by histology. Methods: We analyzed individual data for adults (15-99 years) diagnosed with a brain tumor (ICD-O-3 topography code C71) during 2000-2014, regardless of tumor behavior. Data underwent a 3-phase quality control as part of CONCORD-3. We estimated net survival for 11 histology groups, using the unbiased nonparametric Pohar Perme estimator. Results: The study included 556,237 adults. In 2010-2014, the global range in age-standardized 5-year net survival for the most common sub-types was broad: in the range 20%-38% for diffuse and anaplastic astrocytoma, from 4% to 17% for glioblastoma, and between 32% and 69% for oligodendroglioma. For patients with glioblastoma, the largest gains in survival occurred between 2000-2004 and 2005-2009. These improvements were more noticeable among adults diagnosed aged 40-70 years than among younger adults. Conclusions: To the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors by histology in adults. We have highlighted remarkable gains in 5-year survival from glioblastoma since 2005, providing large-scale empirical evidence on the uptake of chemoradiation at population level. Worldwide, survival improvements have been extensive, but some countries still lag behind. Our findings may help clinicians involved in national and international tumor pathway boards to promote initiatives aimed at more extensive implementation of clinical guidelines. (© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu